Terns Pharmaceuticals Competitors and Similar CompaniesClear all

Terns Pharmaceuticals's competitors and similar companies include Novartis, Fortrea and Rigel Pharmaceuticals.

	Terns Pharmaceuticals Terns Pharmaceuticals is a biopharmaceutical company developing small-molecule single-agent and combination therapy for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases.	Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products.	Fortrea Fortrea Holdings (formerly known as Labcorp Clinical Development and Commercialization Services) is a contract research organization (CRO).	Rigel Pharmaceuticals Rigel Pharmaceuticals develops small-molecule drugs for the treatment of autoimmune diseases, cancer and metabolic diseases.
Founding Date	Founding Date 2017	Founding Date 1996	Founding Date 2023	Founding Date 1996
Type	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development oncology pharma	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Foster City, US HQ	Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more	Locations Durham, US HQ Buenos Aires, AR Melbourne, AU Sydney, AU Zaventem, BE Sao Paulo, BR Sofia, BG see more	Locations South San Francisco, US HQ
Employees	Employees 59	Employees 75,883	Employees 19,000	Employees 1633% increase
Valuation ($)	Valuation ($) 580.9 m	Valuation ($) N/A	Valuation ($) 1.6 b	Valuation ($) 256 m
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $56.7b (FY, 2025)	Revenue (est.) $2.7b (FY, 2025)	Revenue (est.) $294.3m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods $8.4b (FY, 2025)	Cost of goods N/A	Cost of goods $19.6m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit $49.8b (FY, 2025)	Gross profit N/A	Gross profit $274.7m (FY, 2025)
Net income	Net income ($96.2m) (FY, 2025)	Net income $14b (FY, 2025)	Net income ($986.2m) (FY, 2025)	Net income $367m (FY, 2025)
Funding
Total funding raised	Total funding raised $ 30m	Total funding raised $ 6.5m	Total funding raised N/A	Total funding raised $ 130m